Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.

@article{Clauw2008MilnacipranFT,
  title={Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial.},
  author={Daniel J. Clauw and Philip J Mease and Robert W. H. Palmer and R Michael Gendreau and Yong Wang},
  journal={Clinical therapeutics},
  year={2008},
  volume={30 11},
  pages={1988-2004}
}
BACKGROUND Preclinical and clinical studies have suggested that milnacipran, a dual norepinephrine-serotonin reuptake inhibitor, may be efficacious in the treatment of fibromyalgia (FM). OBJECTIVE This study was conducted to evaluate the efficacy and tolerability of milnacipran in treating the multiple domains of FM. METHODS This was a multicenter, double-blind, placebo-controlled trial. Adult patients (age 18-70 years) who met 1990 American College of Rheumatology criteria for FM were… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 103 extracted citations

Milnacipran: beyond a role of antidepressant.

Clinical neuropharmacology • 2009
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…